magnesium gluconate

PreclinicalSmall molecule

NNational Center for Research Resources (NCRR)

magnesium gluconate is one of 4 small molecule programs targeting Cholestatic liver disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cholestatic Liver DiseaseActive, not recruiting

Cholestatic Liver DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Cholestatic Liver Disease

#DrugCompanyPhaseTrials

Rocaltrol

Jazz Pharmaceuticals

Approved

1 2

Lipaglyn

ZZydus Therapeutics Inc.

Phase 1

2 3

Epsom Salt

FFresenius Kabi USA, LLC

Preclinical

1 4

magnesium gluconate

NNational Center for Research Resources (NCRR)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cholestatic liver disease1 trial

Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease

Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00007033·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for magnesium gluconate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — magnesium gluconate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for magnesium gluconate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Center for Research Resources (NCRR) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Center for Research Resources (NCRR)

magnesium gluconate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cholestatic liver disease1 trial

References

Drug Info

Quick Facts

Related News